ASX 200 healthcare stock tumbles amid $200 million US acquisition

The ASX 200 healthcare company is acquiring a US medical technology business.

| More on:
Health professional looking at a laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) healthcare stock Sonic Healthcare Ltd (ASX: SHL) is taking a tumble today.

Shares in the global pathology provider closed yesterday trading for $30.50. At the time of writing on Thursday, shares are swapping hands for $29.09 apiece, down 4.6%.

That sees the healthcare share underperforming the ASX 200 today, with the benchmark index down 0.5% at this same time.

This comes following news of a United States-based medical acquisition.

What medical asset is the ASX 200 healthcare stock acquiring?

The Sonic Healthcare share price is dipping after the ASX 200 healthcare stock reported that it has signed binding agreements to acquire Pathology Watch.

Located in the US state of Utah, the medical technology business has developed and commercialised an integrated, end-to-end digital pathology platform for skin pathology.

Sonic will pay US$130 million (AU$200 million) for business, which it will fund from existing cash and debt facilities. Management said it does not consider the transaction to be material for Sonic Healthcare.

Management noted that Pathology Watch is currently at pre-profit stage. However, they expect to "achieve attractive earnings per share and return on invested capital accretion" over the coming years.

The ASX 200 healthcare stock said the opportunities include accelerating Sonic's transition to digital pathology; providing a competitive advantage in existing dermatopathology markets; and promoting "significant synergies" with its AI partner, Franklin.ai.

Commenting on the acquisition, Sonic CEO Colin Goldschmidt said:

The acquisition of Pathology Watch is an important and enormously exciting step in Sonic's transition to digital pathology and pathology AI and offers multiple avenues for value creation.

He added that the next steps are to work with Pathology Watch to "enhance our digital pathology and AI strategy, and to provide competitive advantage for Sonic through a superior service offering to referring physicians and their patients".

The founders, management team and staff of Pathology Watch are expected to stay on with the business.

The acquisition remains subject to customary conditions. Sonic expects to close the transaction in December.

Sonic Healthcare share price snapshot

Today's fall has pushed the ASX 200 healthcare stock back into the red for 2023.

Since the opening bell on 3 January, the Sonic Healthcare share price is now down 1%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Healthcare Shares

These healthcare stocks could be set to double according to broker

Interested in gaining exposure to the healthcare sector? These options could be ones to watch. 

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Up 250% in a year, how much higher can this ASX healthcare share climb?  

The future looks promising for this biotech firm after delivering a record-quarterly result.

Read more »

shadow of a man looking out a window with arrows signifying falling share price
Healthcare Shares

Macquarie expects this ASX All Ords healthcare stock to fall 21% in FY26

The company faces several headwinds across multiple divisions.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Top broker names the best ASX healthcare shares to buy in FY26

Bell Potter has good things to say about these shares.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is jumping on record quarter?

This stock reported record sales during the past three months.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'

If you haven’t heard of this fast-rising ASX 200 stock yet, that’s about to change.

Read more »